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Abstract. Gliosarcomas are rare and poorly characterized malignant brain tumors that exhibit a biphasic tissue pattern with
areas of gliomatous and sarcomatous differentiation. These tumors are histological variants of glioblastoma, displaying a similar
genetic profile and dismal prognosis. Up-regulation of PDGFR subfamily of tyrosine kinase members, PDGFR-α and c-Kit,
and their intracellular effectors RAS/RAF/MAPK has a crucial role in the cancer development. In addition, signal transduction
mediated by activating mutations of c-Kit and PDGFR can be effectively blocked by specific tyrosine kinase inhibitors, such
as Imatinib mesylate. The aim of this study was to characterize the molecular alterations of PDGFR signaling in gliosarcomas.
Six cases were analyzed by immunohistochemistry for the expression of PDGFR-α, c-Kit and their ligands PDGF-A and SCF,
respectively. The cases were further evaluated for the presence of activating mutations of PDGFR-α (exons 12 and 18) and c-kit
(exons 9, 11, 13, and 17), as well as B-RAF (exons 11 and 15). Expression of PDGF-A was found in all cases and co-expression
of PDGFR-α was observed in three cases. Four cases showed expression of SCF, and c-Kit was observed only in one case that
also expressed SCF. Generally, immunoreaction predominates in the glial component. The mutational analysis of PDGFR-α
showed the presence of an IVS17-50insT intronic insertion in two cases, one of them also with a 2472C > T silent mutation;
this silent mutation was also found in another case. Glioma cell line analysis of IVS17-50insT insertion showed no influence
on PDGFR-α gene splicing. No mutations were detected in c-kit and B-RAF oncogenes. Our results indicate that activating
mutations of PDGFR-α, c-kit and B-RAF are absent in gliosarcomas. Nevertheless, the presence of a PDGFR-a/PDGFA and
c-Kit/SCF autocrine/paracrine stimulation loop in a proportion of cases, supports the potential role of specific tyrosine kinase
inhibitors in the treatment of gliosarcomas.
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1. Introduction
Gliosarcoma is a rare tumor of the central ner-
vous system (CNS), characterized by the presence
of a biphasic tissue pattern with alternating areas
of malignant gliomatous and sarcomatous differenti-
ation [36]. Gliosarcoma is a variant of glioblastoma,
World Health Organization (WHO) grade IV, with
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less than 1 year median survival despite all treatment
modalities [36]. Gliosarcomas disclose genetic pro-
file similar to glioblastomas, with a high frequency
of PTEN mutations, p16 homozygous deletions, and
also TP53 mutations, but for the absence or low fre-
quency of EGFR overexpression/amplification [1,32,
36,38]. The histogenesis of gliosarcomas has been a
matter of controversy. Recently, several studies showed
the presence of identical genetic alterations in both
(glial and mesenchymal) components, supporting the
concept of their monoclonal origin [1,6,32,38].
Receptor protein tyrosine kinases (RTKs) are cen-
tral regulators of growth signaling and their con-
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stitutive activation, through genetic alterations, has
been related with the oncogenesis of several neo-
plasms, including glioblastomas [44]. Platelet-derived
growth factor receptor alpha (PDGFR-α) and c-Kit
belong to the PDGFR subfamily or class III RTKs,
which also includes PDGFRβ, FMS-related tyrosine
kinase 3 (FLT3), and colony-stimulating factor I re-
ceptor (CSF1R) [5]. Both PDGFR-α and c-kit are lo-
cated on chromosome 4p12 and have functional and
structural homologies [18]. This PDGFR subfamily
is characterized by an extracellular region with five
immunoglobulin-like domains, a transmembrane re-
gion and an intracellular region with a regulatory jux-
tamembrane domain, and a catalytic tyrosine kinase
domain. The binding of cognate ligands to PDGFR
induces dimerization of the receptor leading to au-
tophosphorylation of tyrosine residues and stimula-
tion of kinase activity, with consequent recruitment of
downstream intracellular cascades RAS/RAF/MAPK,
PI3K/AKT and STATs, that regulate cell proliferation,
differentiation, migration and survival [27]. The devel-
opment of Imatinib mesylate (Gleevec R©, Novartis), a
selective inhibitor of tyrosine kinases, including c-abl,
c-kit and PDGFR, highlights the implications of these
receptors not only in the oncogenic mechanisms but
also in the treatment of patients with tumors harbor-
ing alterations of these tyrosine kinases [8]. Imatinib
is highly effective in the treatment of gastrointestinal
stromal tumors (GISTs) with activating mutations of c-
kit, mainly in exon 11, and is also effective in GISTs
with alternative activating mutations of PDGFR-α [22,
23].
PDGFR-α and its best-characterized ligand (PDGF-
A) are major proliferation factors for mesenchymal,
smooth muscle and glial cells, and play an impor-
tant role in normal development, especially of the
CNS [39]. In glioblastomas, the overexpression of
PDGFR-α and PDGF-A is consistent with an onco-
genic autocrine loop [17,19,24,35,48]. Amplification
of PDGFR-α has been considered an infrequent event,
observed in approximately 10% of glioblastomas [48].
However, a recent study reports a frequency of 29%
of glioblastomas with PDGFR-α amplification [28].
Expression of c-kit and its ligand, stem cell factor
(SCF), is important for hematopoiesis, gametogenesis,
melanogenesis and development of interstitial cells of
Cajal [2]. Overexpression of c-kit/SCF is thought to
play a role in neoplasms either through mutations of c-
kit (e.g. GISTs) or by autocrine/paracrine growth stim-
ulation (e.g. small cell lung cancer) [18]. Expression of
both c-kit/SCF in glioma cell lines has been reported,
but so far, there are no reports in human gliomas [20,
42]. The few studies concerning c-kit in glioblastomas,
showed absence or low frequency of c-kit overexpres-
sion and absence of c-kit mutations [28,33,41,46].
Deregulation of cell proliferation in neoplasms can
also be accomplished by up-regulation of RAS/RAF/
MAPK intracellular signaling pathway [16]. Mutations
of RAS oncogene are found in around 30% of human
tumors [16]; however, RAS alterations have been rarely
identified in gliomas [7,13]. Recently, our group and
others reported the presence of B-RAF activating mu-
tations in a small fraction (3–11%) of glioblastomas [3,
13,29]. B-RAF is a member of the RAF family of ser-
ine/threonine cytoplasmatic kinases. The primary con-
sequence of B-RAF mutation is constitutive kinase ac-
tivation, with consequent stimulation of downstream
targets, independently of RTK and RAS status [45].
In the present work we intended to evaluate the role
of PDGFR-α/PDGF-A, c-kit/SCF and B-RAF, in the
pathogenesis of gliosarcomas. We performed the eval-
uation of PDGFR-α, PDGF-A, c-Kit, and SCF im-
munohistochemical expression in the gliomatous and
sarcomatous components of 6 bona-fide gliosarcomas.
In addition, we studied the molecular alterations of
hotspot regions of c-kit (exons 9, 11, 13 and 17),
PDGFR-α (exons 12 and 18) and B-RAF (exons 11 and
15) oncogenes, in order to clarify the potential use of
kinase inhibitor-based therapies in gliosarcomas.
2. Material and methods
2.1. Patients and tumor samples
Six formalin-fixed, paraffin-embedded cases of glio-
sarcoma were retrieved from the pathology archives of
the Department of Pathology, Hospital S. João, Porto,
Portugal. All cases have been previously character-
ized [38]. The clinical pathologic information was ob-
tained from the surgical pathologic reports: two men
and four women with a mean age of 62 years (age
range of 55–72 years); the most frequent (5/6) cerebral
tumor location was the temporal region.
2.2. Cell lines
Human glioma-derived A-172, SW 1088 and U-87
MG tumor cell lines were kindly provided by Prof.
M. Mareel, Laboratory of Experimental Cancerology,
University Hospital, Ghent, Belgium. Cells were main-
tained in Eagle’s Minimum Essential Medium (MEM)
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supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/ml penicillin and streptomycin (Gibco,
Paisley, UK) in a humidified incubator at 37◦C in 5%
CO2 atmosphere. Routinely, the medium was replaced
every 2–3 days.
2.3. PDGF-A, PDGFR-α, SCF and c-kit
immunohistochemistry
Immunohistochemistry procedure was performed
according to streptavidin–biotin–peroxidase complex
principle, using rabbit polyclonal anti-human antibod-
ies raised against PDGF-A (dilution 1 : 80; clone N-30,
Santa Cruz Biotechnology, Santa Cruz, CA), PDGFR-
α (dilution 1 : 175; RB-9027-P, LabVision Corp, Fre-
mont, CA), c-kit (dilution 1 : 50; clone A 4502, DAKO
Corporation, Carpinteria, CA), and mouse monoclonal
antibody raised against SCF (dilution 1 : 200; clone
G-3, Santa Cruz Biotechnology, Santa Cruz, CA).
Briefly, deparaffinized and rehydrated sections used
to study PDGF-A expression were pre-treated by mi-
crowaving in 10 mM citrate buffer (pH 6.0) three
times for 5 minutes at 600 W. The sections used in
PDGFR-α expression study were submitted to heat-
induced epitope antigen retrieval with 10 mM citrate
buffer (pH 6.0) for 20 minutes; for SCF immunoex-
pression analysis the same antigen retrieval procedure
was used with EDTA (pH 8.0). No antigen retrieval
was used for c-kit immunoexpression. After incubation
with primary antibody at room temperature, PDGF-A,
and PDGFR-α for 30 minutes or 2 hours for SCF and
c-kit, the secondary biotinylated goat anti-polyvalent
antibody was applied for 15 minutes followed by in-
cubation with streptavidin–peroxidase complex. The
immune reaction was visualized by DAB as a chro-
mogen (Ultravision Detection System Anti-polyvalent,
HRP/DAB; Lab Vision, Fremont, CA). Appropriated
positive and negative controls were included in each
run: GIST samples were included as SCF and c-kit pos-
itive controls (tumor cells) as well as cells that were
internal c-kit negative controls (smooth muscle cells
of muscularis mucosa and muscularis propria). For
PDGF-A and PDGFR-α, cutaneous–mucosa transition
of the anal region, namely medium dimension vessels
with a muscular layer were used as positive controls.
For negative controls, primary antibodies were omitted
and also primary antibodies were replaced by another
irrelevant antibody (CEA, rabbit anti-human, DAKO
Corporation, Carpinteria, CA) produced from the same
species that produced the primary antibody. All sec-
tions were counterstained with Gill-2 haematoxylin.
The immunohistochemical reactions were analyzed
in blind fashion protocol, and immunoreactivity was
assessed as described previously [10]. Only tumor cell
with an intense cell–membrane-bound and/or intracy-
toplasmatic immunoreactivity were evaluated as posi-
tive. A very faint or nuclear staining was not consid-
ered positive. Sections were scored semiquantitatively,
in both glial and mesenchymal components as follows:
(−), 0% of immunoreactive cells; (+), <5% of im-
munoreactive cells; (++), 5–50% of immunoreactive
cells; and (+ + +), >50% of immunoreactive cells.
Samples with scores (−) and (+) were considered neg-
ative, and those with scores (++) and (+ + +) were
considered positive.
2.4. DNA extraction
Tumor DNA was obtained from paraffin sections as
previously described [3]. Briefly, serially 10 µm thick
unstained sections were obtained, with one 4 µm H&E
section for identification and selection of the sarcoma-
tous and gliomatous components, and the selected por-
tions excised using sterile blades. In four cases (GS1,
GS2, GS5 and GS6), we were able to dissect both
components separately. Paraffin was removed by in-
cubation in xylene, followed by ethanol washing, ace-
tone precipitation, drying and then digestion with ap-
proximately 100 µl of lyses buffer (500 mM Tris-HCl
[pH 8.5], 1 mM EDTA [pH 8.0]) containing proteinase
K (Roche, Mannheim, Germany) at a final concentra-
tion of 0.5 mg/ml, at 55◦C for 48 hours. After pro-
teinase K denaturation, DNA samples were stored at
−20◦C for subsequent molecular analysis.
For human cell lines, DNA was extracted accord-
ing to salting out procedure, with some modifications.
Briefly, cells pellets were dissolved in Sodium/EDTA
buffer and digested with proteinase K (Roche, Mann-
heim, Germany) at a final concentration of 0.5 mg/ml,
at 55◦C. After overnight incubation, saturated NaCl
and chloroform were added to the suspension allowing
proteins and DNA separation. DNA precipitation was
performed with isopropanol. Finally, DNA was washed
with 70% ethanol and dissolved in Tris/EDTA buffer.
The concentrations were determined by spectropho-
tometry and aliquot DNA stored at −20◦C until use.
2.5. Screening for c-kit, PDGFR-α, and B-RAF
mutations
2.5.1. PCR amplification
Screening of c-kit mutations (exons 9, 11, 13 and 17)
was carried out by PCR, followed by direct sequencing
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and pre-screening of PDGFR-α (exons 12 and 18), and
B-RAF mutations (exons 11 and 15) was done by PCR
– single-strand conformational polymorphism (PCR-
SSCP) followed by direct DNA sequencing of samples
that showed a mobility shift in the PCR-SSCP analysis.
Briefly, PCR was carried out with 2 µl of DNA solu-
tion, 0.2–0.6 µM of both sense and antisense primers,
0.2 mM of dNTPs, MgCl2 (1.5–1.75 mM), 20 mM
Tris-HCl (pH 8.4), 50 mM KCl and 1 U of Platinum
Taq polymerase (Invitrogen, Life Technologies Inc.,
UK) in a final volume of 25 µl. Thirty-seven cycles of
denaturation (94◦C), annealing (58–60◦C) and exten-
sion (72◦C) for 45 s each were carried out in a ther-
mocycler (BioRad, Hercules, CA, USA). Primer se-
quences were previously described [3,11,23].
2.5.2. PCR-SSCP
PCR products of PDGFR-α and B-RAF exons were
mixed with an equivalent volume of the denaturing
loading buffer (98% formamide, 0.05% xylene cyanol
and bromophenol blue). After denaturating at 95◦C for
10 minutes and quenched on ice, 15 µl of the mixture
were loaded onto 0.8X MDE gel (Cambrex, Rockland,
USA). Gels were run at 180 V, 4◦C for 16–20 h, silver
stained and dried at 80◦C for 2 h.
2.5.3. Direct sequencing
The PCR products were first purified using
a MicroSpinTM S-400 HR Columns (Amersham Bio-
sciences, Piscataway, NJ, USA). Purified PCR prod-
ucts were submitted to a cycle sequencing reaction
using an ABI PRISM BigDye Terminator Cycle Se-
quencing Ready Reaction Kit (Applied Biosystems,
Foster City, CA, USA) and analyzed in an ABI PRISM
3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s in-
structions.
2.6. Detection of alternative RNA splicing by reverse
transcriptase–PCR
Total RNA from human glioma-derived cell lines
was extracted using the Trizol R© (Invitrogen, Life
Technologies Inc., UK) method according to the man-
ufacturer’s instructions. Briefly, cell pellets were im-
mersed in Trizol and homogenized. Proteins were re-
moved with chloroform and the RNA pellets were
washed once with isopropyl alcohol, and once with
75% ethanol. The total RNA pellets were reconstituted
in RNase free water (Ambion, Cambridge, UK).
Reverse transcriptase (RT)–PCR was performed ac-
cording to manufacturer, using a set of primers de-
signed to amplify a region overlapping exon 17 to
exon 19: 5′-TATCAAGTTGCCCGAGGAAT-3′ (for-
ward) and 5′-GATCTCCCAGAGCAGAATGC-3′ (re-
verse). First-strand cDNA synthesis was initiated by
incubating 100 ng total RNA with 5 µg/µl oligo(deo-
xythymidine) primers and 1 mM dNTPs, for 5 min
at 65◦C. The following reaction mixture, consisting
of 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM
MgCl2, 10 mM DTT, 40 U RNaseOUT
TM Recombi-
nant RNase Inhibitor and 1 U SuperscriptTM II RT (In-
vitrogen, Life Technologies Inc., UK) in 20 µl total
volume, was added to each RNA/primer mixture pre-
pared previously and incubated at 42◦C for 50 min.
The synthesis was terminated by an incubation at 70◦C
for 15 min and the addition of 2 U E. coli RNase H.
Amplification of the target cDNA was performed with
2 µl RT cDNA products, 0.2 µM each primer, 0.2 mM
of dNTPs, 1.5 mM MgCl2, 20 mM Tris-HCl (pH 8.4),
50 mM KCl and 1 U of Taq DNA polymerase (Fermen-
tas, Lithuania) in a final volume of 25 µl. Thirty-five
cycles of denaturation (94◦C, 15 s), annealing (56◦C,
30 s) and extension (72◦C, 1 min) were carried out in
a thermocycler (BioRad, Hercules, CA, USA).
3. Results
Immunohistochemical results of PDGF-A, PDGFR-
α, SCF and c-kit expression in gliomatous and sarco-
matous components of gliosarcomas are summarized
on Table 1. The staining of the positive cases was pre-
dominantly cytoplasmatic, without any case with ex-
clusive membranal staining. Controls for both posi-
tive and negative immunohistochemistry reaction gave
appropriated results. Positive expression of PDGF-A
was found in all cases: three with similar immunoex-
pression in both (glial and mesenchymal) components
(Fig. 1A); two with expression in the glial component,
and one in the mesenchymal component. Positive co-
expression of PDGFR-α (Fig. 1B) and PDGF-A was
observed in the glial component of three cases. SCF
was positive in the glial component of four cases, one
of them also in the mesenchymal component (Fig. 1C).
Simultaneous SCF and c-kit positive immunoexpres-
sion was identified in both components of one case
(GS 4) (Fig. 1D). Overall, PDGF-A, PDGFR-α, SCF
and c-kit expression was heterogeneous, but predomi-
nate in the glial component of gliosarcomas.
The mutational analysis of PDGFR-α revealed the
presence of an IVS17-50insT insertion at intron 17
(Fig. 2A) in two gliosarcomas (GS 3 and GS 4), and
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Table 1
Immunohistochemistry and mutation features in gliosarcomas
Case Area Immunohistochemistry∗ Mutational status
PDGF-A PDGFR-α SCF c-kit PDGFR-α c-kit B-RAF
GS1 G ++ ++ + − normal nd normal
S ++ + − − normal nd normal
GS2 G ++ ++ ++ − normal nd normal
S ++ + − − normal nd normal
GS3 G + + + − IVS17-50insT
S ++ − − − 2472C > T nd normal
GS4 G +++ + ++ ++ IVS17-50insT normal normal
S +++ − ++ ++
GS5 G +++ ++ ++ − 2472C > T nd normal
S + − + − 2472C > T nd normal
GS6 G +++ − ++ − normal nd normal
S + − − − normal nd normal
G, gliomatous component; S, sarcomatous component; nd, not determined.
∗Scores as described in Material and methods.
Fig. 1. Immunohistochemical expression of PDGF-A (A);
PDGFR-α (B); SCF (C) and c-kit (D) in gliosarcomas (amplifica-
tion: A–C, 200×; D, 400×).
a base substitution 2472C > T (Fig. 2B), leading to a
silent mutation Val824Val on exon 18 in two cases (Ta-
ble 1). One case (GS 3) exhibited both aforementioned
alterations (Table 1). There was no correlation between
mutation status and PDGFR-α expression. The c-kit
mutation analysis of the gliosarcoma that exhibit c-
kit overexpression (GS 4) did not reveal any muta-
tion. No mutations were identified on B-RAF gene (Ta-
ble 1).
Fig. 2. Sequencing analysis of PDGFR-α: (A) insertion of a thymine
(arrow) at position minus 50 of intron 17 (sense strand); and (B) cy-
tosine to thymine substitution (arrow) at nucleotide 2472, resulting
in silent mutation (antisense strand).
The mutational analysis of B-RAF, c-kit and PDGFR-
α genes in glioma-derived cell lines showed the ab-
sence of B-RAF and c-kit mutations and the presence
of the IVS17-50insT insertion at intron 17 of PDGFR-
α in all cell lines. SW 1088 cell line was heterozygous
for the inserted thymine, whereas A-172 and U-87 MG
cell lines were homozygous for the insertion (data not
shown). Although the intronic position of the insertion
suggests no biological consequence, we investigated
the possibility of splicing deregulation introduced by
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Fig. 3. Agarose gel showing no differences in fragment length be-
tween genotypes. M, molecular size marker; lane 1, SW 1088 cell
line heterozygous for the inserted intronic thymine; lane 2, A-172
cell line homozygous for the inserted intronic thymine.
the IVS17-50insT insertion. cDNA analysis of ampli-
fied exon 17 to 19 was evaluated either in heterozy-
gous and homozygous cell lines and no differences in
fragment length were detected (Fig. 3).
4. Discussion
Imatinib was initially designed to inhibit the BCR/
ABL fusion kinase protein in chronic myeloid leukemia
and was later discovered that it is also effective against
GISTs harboring c-kit and PDGFR-α mutations, as
well as dermatofibrosarcoma protuberans with translo-
cation involving PDGFB and chronic myelomono-
cytic leukemia with translocation involving PDGFR-
β gene [14,34,37,43]. The molecular characterization
of PDGFR subfamily in gliosarcomas can be impor-
tant for the identification of patients that could bene-
fit from Imatinib based therapy. The development of
strategies that block PDGFR subfamily downstream
signaling components, such as B-RAF, warrant their
analysis in gliosarcomas [16].
The present study analyzed the immunoexpression
of PDGFR-α, PDGF-A, c-kit and SCF, in addition to
the presence of PDGFR-α, c-kit and B-RAF activating
mutations in both components of 6 well-characterized
gliosarcomas. Immunohistochemical reactions showed
the expression of PDGF-A mainly in the gliomatous
component, and half of the cases also expressed its re-
ceptor PDGFR-α, suggesting the existence of an au-
tocrine/paracrine stimulation loop. These results are
in agreement with the well-documented description of
both receptor and ligand overexpression in glioblas-
tomas [48]. Overexpression of PDGF-A was already
reported to be present in the glial component of gliosar-
comas [12]. The mutational analysis of PDGFR-α
showed the presence of a silent mutation in exon 18,
previously identified by our group in breast carcino-
mas [9], and a base insertion on intron 17. This later
alteration was also found in breast phyllodes tumors
and in normal population, and is consistent with a
polymorphism [10]. In addition, our cDNA analysis
showed that PDGFR-α RNA splicing is not affected
by this insertion. None of the gliosarcomas studied
disclosed PDGFR-α mutations, at variance with re-
ports on GISTs, and similar with reports on glioblas-
tomas [21,41]. Therefore, other molecular mechanisms
should be responsible for PDGFR-α overexpression in
gliosarcomas. Noteworthy, a small fraction of gliosar-
comas (3%) were found to display PDGFR-α gene am-
plification [1].
In our series, c-kit overexpression was identified
in one gliosarcoma. Despite the variety of c-kit anti-
bodies and antigen retrieval methodologies, the anti-
body and immunohistochemical method used in our
study are considered as the most sensitive and spe-
cific for c-kit expression evaluation [26,47]. The mu-
tational analysis of this case did not reveal any acti-
vating mutation. These results are in agreement with
recent studies of c-kit in a wide range of neoplasms,
including glioblastomas, where intense immunostain-
ing was rare and none exhibited c-kit mutations [28,41,
46]. Recently, Joensuu et al. found a significant pro-
portion of glioblastomas (47%) with c-kit gene ampli-
fication [28]. We found SCF immunoexpression in half
of the cases, and co-expression of c-kit in one gliosar-
coma. Simultaneous expression of c-kit and SCF has
been reported in several tumors, suggesting the role
of a c-kit/SCF autocrine/paracrine activation loop in
tumorigenesis [4,15,25,40]. Furthermore, studies of
uveal melanoma and small cell lung cancer cell lines
exhibiting c-kit/SCF autocrine loop, even in the ab-
sence of activating c-kit mutations, showed cell growth
inhibition upon Imatinib exposure [30,31].
The absence of activating mutations of B-RAF in
gliosarcomas, supports its minor role in gliomagene-
sis [3,29].
In summary, our results on PDGFR subfamily alter-
ations of six gliosarcomas are similar to those reported
in glioblastomas. PDGFR-α, c-kit and B-RAF activat-
ing mutations were not found in gliosarcomas. Further
studies are needed to determine whether gene amplifi-
cation mechanism is responsible for PDGFR-α and c-
kit overexpression in gliosarcomas. The presence of a
PDGFR-α/PDGFA and c-Kit/SCF co-expression, sup-
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ports the role of their autocrine/paracrine stimulation
loop in gliosarcoma development, and raises the pos-
sible relevance of specific tyrosine kinase inhibitors in
the treatment of gliosarcomas.
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